These findings shed light on EA-mediated improvement in PD by inhibiting the ferroptosis signaling Nrf2/SLC7A11/FTH1/GPX4 pathway and provide a clear understanding of the previously unrecognized anti-ferroptotic mechanism of EA in treating PD. Here, GPX4 is linked to Parkinson disease.